How much CBD (Cannabidiol) should I take daily?

Introduction

Cannabidiol (CBD) is a non-psychoactive compound found in cannabis that has gained attention for its potential therapeutic benefits. Research has explored its effects on various conditions, including sleep disorders, epilepsy, and neurodegenerative diseases. However, the optimal daily dosage of CBD for different conditions remains a topic of ongoing investigation.

Key Insights

High Dosage for Neurodegenerative Diseases:
- In a study on Huntington's Disease, patients were administered approximately 700 mg/day of CBD for 6 weeks. This dosage was found to be neither symptomatically effective nor toxic.
Moderate Dosage for Insomnia:
- A study on primary insomnia used a daily dose of 150 mg of CBD for 2 weeks. The results indicated a reduction in insomnia severity, although CBD did not outperform a placebo.
Variable Dosage for Epilepsy:
- In children with treatment-resistant epileptic encephalopathy, a dose-escalation trial suggested an initial target dose of 5-6 mg/kg/day, with some patients tolerating up to 10-12 mg/kg/day. This dosage was associated with improved seizure control.
Low Dosage for General Health:
- An 8-week study on healthy adults used a daily dose of 50 mg of CBD. This dosage improved sleep quality and enhanced immune cell function without significant changes in mental health or body composition.

Conclusion

The optimal daily dosage of CBD varies depending on the condition being treated. For neurodegenerative diseases, higher doses around 700 mg/day have been studied but were not found to be effective. For insomnia, a moderate dose of 150 mg/day may reduce symptoms, although it may not be more effective than a placebo. For epilepsy, especially in children, a starting dose of 5-6 mg/kg/day, potentially increasing to 10-12 mg/kg/day, has shown promise. For general health improvements in sleep quality and immune function, a lower dose of 50 mg/day may be beneficial.

How much CBD (Cannabidiol) should I take daily?

Summary

Introduction

Key Insights

Conclusion

Sources and full results

Controlled clinical trial of cannabidiol in Huntington's disease

CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with Huntington's Disease.

O049 Insomnia severity and cognitive performance following two weeks’ nightly supplementation with 150mg Cannabidiol (CBD) for primary insomnia

Daily CBD supplementation (150mg) reduced insomnia severity from moderate to subthreshold levels without affecting higher-order cognitive performance.

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study

Cannabidiol (CBD) at a dose of 5-6 mg/kg/day can improve seizure frequency and quality of life in children with treatment-resistant epilepsy, with low risk of THC intoxication.

Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity

Eight weeks of daily 50 mg CBD may improve sleep quality and enhance Natural Killer immune cell function in healthy, younger adults.

A systematic review of cannabidiol dosing in clinical populations

CBD has a potential wide range of activity in various medical contexts, with potential benefits for epilepsy, but more pharmacokinetic studies and phase III trials are needed to determine effective doses.

Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model

CBD exhibits clear signs of hepatotoxicity, possibly of a cholestatic nature, raising concerns about potential drug interactions and CBD's safety.

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

CBD has beneficial effects in patients with schizophrenia, potentially representing a new class of treatment without relying on dopamine receptor antagonism.

Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone in advanced cancer patients.

Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Oral cannabidiol does not show any signals of abuse liability at the doses tested in frequent marijuana smokers, potentially informing regulatory decisions regarding its Schedule I status on the CSA.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

CBD oral solution is generally well-tolerated, with diarrhea, nausea, headache, and somnolence being the most common adverse events, and its pharmacokinetics are generally well-defined.

Try another search